ICARE Social Media Post September 2020

FDA Grants Breakthrough Therapy Status to MK-6482 for Treatment of Patients With VHL Disease-Associated Renal Cell Carcinoma

• By admin in Newsletter Articles & Posts

For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc

 

Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract

• Kidney Cancer, Renal Cancer, von Hippel-Lindau (VHL) Disease